Aldeyra Therapeutics (ALDX) vs Heron Therapeutics (HRTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Heron Therapeutics (HRTX) has outperformed Aldeyra Therapeutics (ALDX) over the past year, losing 76.2% versus a loss of 83.1%. Over five years, ALDX leads with a -89.1% price change compared with -97.3% for HRTX. Aldeyra Therapeutics is the larger company by market cap ($50.7 million vs $48.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALDX | HRTX |
|---|---|---|
| Share price | $0.84 | $0.2525 |
| Market cap | $50.70M | $48.04M |
| 1-day change | +16.39% | -4.39% |
| YTD return | -83.78% | -80.58% |
| 1-year return | -83.06% | -76.18% |
| 5-year return | -89.06% | -97.32% |
| EPS (TTM) | $-0.31 | $-0.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $154.90M |
| Revenue growth (YoY) | — | +7.36% |
| Net income (latest FY) | $-33.85M | $-20.20M |
| Gross margin | — | 73.31% |
| Operating margin | — | -1.64% |
| Net margin | — | -13.04% |
| 52-week high | $5.93 | $1.58 |
| 52-week low | $0.527 | $0.2479 |
| Distance from 52-week high | -85.83% | -84.02% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +685.71% | +2672.28% |
| Average volume | 1.16M | 4.56M |
| Shares outstanding | 60.36M | 190.27M |
| Employees | 6 | 128 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aldeyra Therapeutics
ALDX stock →Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About Heron Therapeutics
HRTX stock →Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
ALDX vs HRTX FAQ
Which is bigger, Aldeyra Therapeutics or Heron Therapeutics?
Aldeyra Therapeutics (ALDX) is larger, with a market capitalization of $50.70M compared with $48.04M for Heron Therapeutics (HRTX).
Which stock has performed better over the past year, ALDX or HRTX?
HRTX returned -76.18% over the past 12 months, compared with -83.06% for ALDX (price return, excluding dividends). Past performance does not predict future results.
Are Aldeyra Therapeutics and Heron Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.